drugset
drugset / Trial / NCT00857025

Beta-Glucan in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

NCT00857025 ↗

Phase 1 Completed 20 enrolled City of Hope Medical Center National Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment

Summary

RATIONALE: Biological therapies, such as beta-glucan, may stimulate the immune system in different ways and stop tumor cells from growing. PURPOSE: This phase I trial is studying the side effects and best dose of beta-glucan in treating patients with locally advanced or metastatic non-small cell lung cancer.

Timeline

Start
2008-11-21
Primary completion
2010-11-24
Completion
2021-05-18

Drugs

EvaluationDrugModalityDoseRoute
Subject MM-10-001 Unknown 2.5 mg Oral
Subject MM-10-001 Unknown 5 mg Oral
Subject MM-10-001 Unknown 7.5 mg Oral
Subject MM-10-001 Unknown 10 mg Oral
Subject MM-10-001 Unknown 15 mg Oral
Subject MM-10-001 Unknown 20 mg Oral
Subject MM-10-001 Unknown 30 mg Oral
Subject MM-10-001 Unknown 40 mg Oral
Subject MM-10-001 Unknown 50 mg Oral
Subject MM-10-001 Unknown 80 mg Oral

Indications

lung cancer